Target intelligence / Profile preview

RNA, U6 small nuclear 223, pseudogene (RNU6-223P)

Target
RNU6-223P
Molecular classification
Pseudogene, Non-coding RNA
01

Overview

RNA, U6 small nuclear 223, pseudogene" (RNU6-223P) is classified as a **pseudogene** of the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is a highly conserved non-coding RNA that is a component of the spliceosome complex, essential for pre-mRNA splicing in eukaryotes[1][2]. However, a *pseudogene* like RNU6-223P typically does not produce a functional product and is not known to play a direct biological role nor serve as a receptor, enzyme, or therapeutic target. Multiple copies and pseudogenes of the U6 snRNA gene exist in the human genome as evolutionary byproducts, but the functional U6 snRNA itself is central to the splicing reaction and RNA processing[2]. Pseudogenes generally do not exhibit known disease associations, are not used as biomarkers, and are not targeted by drugs. **Notes on correctness**: - This target is marked as *incorrect* for inclusion as a molecular target, since RNU6-223P is a non-functional pseudogene rather than a protein, receptor, or RNA species with therapeutic relevance. - The canonical target U6 snRNA is called “RNA, U6 small nuclear” (or just "U6 snRNA"), but the specific pseudogene (223) has no known biological or therapeutic significance[2]. - U6 snRNA itself is not a therapeutic target, but rather a key RNA molecule in the spliceosome machinery[1][2]. - No known molecular function, disease involvement, or drug interactions are attributed to this pseudogene.

Other names
RNU6-223PU6 pseudogene 223

Beyond the preview

Go deeper on RNA, U6 small nuclear 223, pseudogene (RNU6-223P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 223, pseudogene (RNU6-223P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call